A meningococcal B vaccine induces cross-protection against gonorrhea
Clinical and Experimental Vaccine Research
;
: 110-115, 2019.
Article
Dans Anglais
| WPRIM
| ID: wpr-763370
ABSTRACT
PURPOSE:
Neisseria meningitidis and Neisseria gonorrhoeae share between 80% and 90% of their genetic sequence. Meningococcal serogroup B vaccines based on outer membrane vesicles—such as VA-MENGOC-BC—could cross-protect against gonorrhea. The aim of this study was to analyze the incidence rates of gonorrhea and other sexually transmitted diseases with respect to the use of the VA-MENGOC-BC vaccine. MATERIALS ANDMETHODS:
Health statistics between 1970 and 2017 were reviewed and the incidence of meningococcal disease and sexually transmitted diseases (gonorrhea, syphilis, condyloma acuminatum, hepatitis B and human immunodeficiency virus infection) were analyzed during the pre- and post-vaccination periods. Gonorrhea incidence was also analyzed by age groups.RESULTS:
VA-MENGOC-BC was successfully used to control a meningococcal epidemic in Cuba. The strategy to combat the epidemic was carried out in two stages. The first one was a nationwide mass-vaccination campaign from 1989 to 1990, targeting the population at highest-risk aged 3 months to 24 years. During the second stage, begun in 1991, it was included in the Expanded Immunization Program. Gonorrhea incidence increased from 1970 to 1989. However, after the VA-MENGOC-BC massive vaccination campaign a sharp decrease of gonorrhea incidence was observed. It lasted between 1989 and 1993. A second incidence peak was detected in 1995, but it dropped again. Data clearly show a decline in the incidence of gonorrhea following massive vaccination, in contrast with other sexually transmitted diseases. Incidence rates in unvaccinated age groups also decreased, probably due to herd immunity.CONCLUSION:
There is evidence that VA-MENGOC-BC could induce a moderate protection against gonorrhea.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Vaccins
/
Gonorrhée
/
Syphilis
/
Maladies sexuellement transmissibles
/
Incidence
/
VIH (Virus de l'Immunodéficience Humaine)
/
Vaccination
/
Programmes de vaccination
/
Cuba
/
Immunité de groupe
Type d'étude:
Etude d'incidence
/
Étude pronostique
Limites du sujet:
Humains
Pays comme sujet:
Caraïbes
/
Cuba
langue:
Anglais
Texte intégral:
Clinical and Experimental Vaccine Research
Année:
2019
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS